India is poised to play a transformative role in the global fight against obesity as the patent for semaglutide—the key ingredient behind blockbuster weight-loss drugs Wegovy and Ozempic—expires this week. The move is expected to trigger a surge in affordable generic versions, potentially slashing treatment costs by more than half.
Originally developed by Danish pharmaceutical giant Novo Nordisk for diabetes management, semaglutide has gained global attention for its effectiveness in weight loss. The drug belongs to a class known as GLP-1 receptor agonists, which help regulate appetite, slow stomach emptying, and improve blood sugar control.
With the patent expiry in India, major domestic pharmaceutical companies—including Cipla, Sun Pharma, Dr Reddy’s Laboratories, and Biocon—are preparing to launch branded generic versions. Analysts expect dozens of new variants to hit the market within months, intensifying competition and driving prices down significantly.
Currently, monthly treatment with Ozempic or Wegovy can cost between 8,800 and 16,000 rupees. Experts predict generic versions could reduce prices to around 3,000–5,000 rupees, making the drugs accessible to millions more patients.
India, often referred to as the “pharmacy of the world,” is already a global leader in generic drug production. The country supplies around 20% of the world’s generics and has previously played a key role in reducing the cost of life-saving medicines, including HIV treatments.
Health experts believe cheaper semaglutide could significantly impact India’s growing burden of obesity and type-2 diabetes, with over 77 million people affected by the latter. The drugs are increasingly being used not only by endocrinologists but also by cardiologists, orthopaedic surgeons, and respiratory specialists to manage weight-related health conditions.
However, doctors have urged caution. While effective, GLP-1 drugs can cause side effects such as nausea, vomiting, and digestive issues, with rare risks including pancreatitis. There are also concerns about misuse, especially as lower prices may encourage over-the-counter access through unregulated channels such as beauty clinics or online platforms.
Medical professionals stress that these drugs are not a “quick fix” and should be used alongside proper diet, exercise, and medical supervision. Rapid weight loss without adequate nutrition may lead to muscle loss and other health complications.
India’s drug regulator has already issued warnings against misleading advertisements and emphasized that such medications must only be prescribed by qualified healthcare professionals.
As India prepares for a wave of affordable weight-loss drugs, the challenge will be to balance accessibility with strict quality control and responsible usage—an effort that could shape not only its domestic healthcare landscape but also global obesity treatment trends.
